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Background: Low-level laser therapy (LLLT) has been widely used as adjuvant strategy for treatment of
musculoskeletal disorders. The light-tissue interaction (photobiostimulation) promotes analgesic and
anti-inflammatory effects and improves tissue healing, which could justify the recommendation of this therapy for
patients with fibromyalgia, leading to an improvement in pain and possibly minimizing social impact related to this
disease. The present study proposes to evaluate the effect of LLLT on tender points in patients with fibromyalgia,
correlating this outcome with quality of life and sleep.
Methods/design: One hundred and twenty patients with fibromyalgia will be treated at the Integrated Health
Center and the Sleep Laboratory of the Post Graduate Program in Rehabilitation Sciences of the Nove de Julho
University located in the city of Sao Paulo, Brazil. After fulfilling the eligibility criteria, a clinical evaluation and
assessments of pain and sleep quality will be carried out and self-administered quality of life questionnaires will be
applied. The 120 volunteers will be randomly allocated to an intervention group (LLLT, n = 60) or control group
(CLLLT, n = 60). Patients from both groups will be treated three times per week for four weeks, totaling twelve
sessions. However, only the LLLT group will receive an energy dose of 6 J per tender point. A standardized
50-minute exercise program will be performed after the laser application. The patients will be evaluated regarding
the primary outcome (pain) using the following instruments: visual analog scale, McGill Pain Questionnaire and
pressure algometry. The secondary outcome (quality of life and sleep) will be assessed with the following
instruments: Medical Outcomes Study 36-item Short-Form Health Survey, Fibromyalgia Impact Questionnaire, Berlin
Questionnaire, Epworth Sleepiness Scale and polysomnography. ANOVA test with repeated measurements for the
time factor will be performed to test between-groups differences (followed by the Tukey-Kramer post hoc test), and
a paired t test will be performed to test within-group differences. The level of significance for the statistical analysis
will be set at 5% (P ≤0.05).
Trial registration: The protocol for this study is registered with the Brazilian Registry of Clinical Trials – ReBEC
(RBR-42gkzt)* Correspondence: paulo.tarso@uninove.br
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According to the American College of Rheumatology
(ACR), fibromyalgia is a chronic musculoskeletal condi-
tion characterized by generalized pain for at least three
months in combination with sensitivity in 11 or more of
the 18 points sensitive to palpation in different parts of
the body, known as tender points [1,2]. Fibromyalgia
was not a clinically well-defined condition before the
1970s, and unlike what was thought in the past, this is
not an inflammatory condition and does not lead to joint
impairment or deformities. However, the chronic nature
of this condition has a negative impact on quality of
life [3].
The most widely accepted theory is that fibromyalgia
is caused by an abnormality in pain modulation mechan-
isms - a central nervous system disorder in regulating
sensitivity to pain. Thus, an individual may exhibit a re-
duction in serotonin (neurotransmitter of the inhibitory
descending system) and in increase substance P (neu-
roexcitatory substance involved in the conduction of
pain) in the central nervous system [4].
Fibromyalgia is often associated with other syndromes,
such as fatigue, sleep disorders, morning stiffness and
psychological disorders, such as anxiety and depression.
Sleep disorders are closely linked to somatic symptoms
in patients with fibromyalgia and not to their personal-
ity. The most common complaints are difficulty falling
asleep, frequent awakening during the night, difficulty
getting back to sleep, restless superficial sleep and early
rising, the consequences of which are nonrestorative
sleep and a sensation of weariness, which contribute to-
ward a poor quality of life. Thus, non-restorative sleep is
an important aspect among the manifestations of fibro-
myalgia, which makes the investigation into primary
sleep disorders essential to the assessment of affected
individuals [5,6]. The complexity of the factors involved
regarding both diagnosis and adequate treatment under-
scores the need for further studies aimed at broadening
knowledge on the effects of this condition on patients.
There are several treatment options for fibromyalgia,
such as drugs [7,8], psychotherapy [9], hydrotherapy
[10], electrotherapy [11], exercise [12] and laser therapy
[13,14]. However, there is no consensus or defined
protocol regarding the use of these treatment options.
Low-level laser therapy (LLLT) is one of the more recent
pain treatment modalities in the field of physical ther-
apy. According to Laakso et al. [15], the analgesic effect
of phototherapy may be mediated by hormonal/opioid
mechanisms, the responses of which depend directly on
the dose and wavelength used to irradiate the tissue.
Thus, the parameters directly affect the results. LLLT is
also reported to act on peripheral neural stimulation
and the regulation of microcirculation, interrupting
pain mechanisms and promoting analgesia [16]. Thenormalization of microcirculation and the capacity of
neural transmission obtained through laser therapy have
been described as responsible for the interruption of
the vicious circle that gives rises to and perpetuates
pain [13].
In last ten years, important advances have occurred
in the therapeutic use of photobiostimulation with
low-level lasers. Such advances have occurred due to a
greater understanding of the mechanisms of action
involved as well as technological developments and the
publication of relevant studies and research related to
the advantages obtained with the use photobiostimula-
tion in clinical practice. However, the lack of consensus
regarding therapeutic protocols hinders multicenter
comparisons of the many clinical trials published. Thus,
a number of scientific papers have been drafted to estab-
lish a therapeutic protocol for the use of photobiostimu-
lation with regard to exposure time, intensity, energy
density, application mode and application site.
A considerable number of studies have demonstrated
the remission of pain in patients with fibromyalgia
through the use of LLLT. However, this is not yet a well-
established therapy and comparisons of controlled
clinical trials are rare. Moreover, there are problems
regarding the standardization of treatment [13,14,17,18].
In the investigation of complex phenomena such as
fibromyalgia, the application of multiple methodological
techniques enables a better assessment and understand-
ing of such phenomena [19].
The aim of the proposed study is to assess the anal-
gesic effect of LLLT on tender points in patients with
fibromyalgia and establish correlations with quality of
life and sleep.
Methods and study design
Characterization of proposed study
A double-blind randomized controlled trial will be car-
ried out at the Sleep Study Laboratory of the Post
Graduate Program in Rehabilitation Sciences of the
Nove de Julho University (UNINOVE) and the UNIN-
OVE Integrated Health Center, located in the city of Sao
Paulo, Brazil. (Figure 1)
Characterization of subjects
The sample will be comprised of 120 patients with fibro-
myalgia with a clinical diagnosis based on the ACR cri-
teria. The subjects will be screened at the UNINOVE
Rheumatology Clinic.
Composition of sample
The required sample size was determined for the pri-
mary outcome variable, that is, overall score of the
Fibromyalgia Impact Questionnaire (FIQ). According to
Bennett et al. [20], a clinically relevant change is a 15 to
Figure 1 Flow chart characterization of the experimental design, sample composition and trial protocol.
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an approximate 10 to 15 points reduction). Assuming a
unilateral alternative (that is, the intervention reduces
the impact of fibromyalgia), we can detect differences ofat least 15% with a power of 95% and α of 0.05 with two
groups (intervention and usual control group) of 45 par-
ticipants, with a mean in the FIQ of approximately 70
and a standard deviation of approximately 20 points.
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recruit a total of 60 women with fibromyalgia for each
group. We will recruit a total of 120 women with fibro-
myalgia (that is, one LLLT intervention group and con-
trol group of 60 persons each).
Inclusion criteria
The following criteria will be adopted as requirements
for inclusion in the study:
 A clinical diagnosis of fibromyalgia based on ACR
criteria;
 Cognitive level sufficient for understanding the
procedures and following the instructions;
 Agreement to participate in the study and the
signing of a statement of informed consent after
receiving clarifications regarding the objectives of
the study.
Exclusion criteria
Patients with the following will be excluded from the
study:
 Psychiatric disorders, history of drug abuse or other
behavior that requires psychiatric medication
intervention;
 Development of situations beyond clinical control
that do not allow participation in aerobic training
activities, exertion or group activities;
 Severe physical disability;
 Co-morbid condition (irritable bowel syndrome,
intestinal cystitis, and others);
 Uncontrolled endocrine disorders;
 Although there is no description of serious
complications in individuals submitted to LLLT,
those with a history of epilepsy, seizures, heart
disease, arrhythmia, pacemaker, undiagnosed pain,
pregnancy and malignant tumors will be excluded
from the study.
Composition of groups and randomization
After the initial evaluation, the 120 volunteers will be
randomly allocated to an intervention group (LLLT; n =
60) or control group (CLLLT; n = 60). Randomization
numbers will be created using a randomization table at a
central office, where a series of sealed, opaque, num-
bered envelopes will be used to ensure confidentiality.
Each envelope will contain a card indicating the group
in which the patient will participate. After fulfilling the
eligibility criteria, a clinical evaluation and assessments
of pain and sleep quality will be carried out and self-
administered quality of life questionnaires will be applied
(Fibromyalgia Impact Questionnaire, Medical Outcomes
Study 36-item Short-Form Health Survey and McGillPain Questionnaire). After the volunteer signs the state-
ment of informed consent, she will randomly select one
of the envelopes. This study received approval from the
UNINOVE Human Research Ethics Committee (proto-
col number 474921). Additionally, the study is registered
with the World Health Organization Universal Trial
Number (UTN) U1111-1125-5007 and the Brazilian
Registry of Clinical Trials (number - RBR-42gkzt).
Blinding procedures
A single examiner with the necessary skills will perform
the evaluations in order to achieve reproducible exami-
nations and more reliable results. A second examiner
will be trained to administer the laser and conduct the
exercises. A third examiner will perform the re-
evaluations of the two groups. The groups will not
be identified in order to avoid ‘unmasking’ during
the study.
Experimental protocol
Evaluation and educative session
The evaluations will occur prior to and at the end of the
therapeutic program by a researcher with no knowledge
regarding the type of treatment to which the subjects
will be submitted. All subjects in both groups will be
submitted to the same evaluation protocol, which will
include the aspects listed below.
Personal data
Age (in years), body mass (in kilograms), height (in
meters), profession, schooling (no schooling, elementary
education, high school education, university education,
postgraduate education) and marital status.
History of pain
Duration of pain, sites of pain in decreasing order of in-
tensity, period of day in which pain is more intense, fac-
tors of improvement and worsening of pain, sleep
quality, type of mattress and pillow.
Visual analog scale for pain
A visual analog scale will be used for the assessment of
pain intensity, consisting of a straight line measuring 10
centimeters, with no numbers displayed and on which
the words ‘no pain’ appear on the left extremity and ‘un-
bearable pain’ appear on the right extremity. The patient
will be instructed to mark a point on the line that indi-
cates the intensity of pain she is feeling at the time.
Higher scores denote greater pain intensity.
Pressure algometry of pain threshold
A pressure algometer (digital algometer, model DDK 20,
manufactured by Kratos Ltd., Cotia, Sao Paulo, Brazil) is
a device that assesses the pain threshold. This device
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pressure (force) gauge. The gauge displays values in kilo-
grams. Because the surface of the rubber tip is 1 cm2,
the readings are expressed in kilogram per square centi-
meter (kg/cm2). The range of the algometer is 0 to 10 kg
and records in 0.1 kg divisions. At one end of the device,
perpendicular pressure is applied to the surface of the
skin and recorded using a manometer. The algometry of
the pain threshold on the tender points will be per-
formed based on the fibromyalgia classification criteria
of the ACR, following the procedures described below:
 The patient will be asked to sit in a chair with feet
supported on the ground and hands supported on
the lap;
 The tender points will be marked with a skin
marking pen and evaluated bilaterally in the
following order: occipital, anterior lower cervical,
trapezius, supraspinatus, second costochondral joint,
lateral epicondyle and medial edge of the knee;
 The patient will be instructed to remain in an
orthostatic position and the tender points of the
gluteus and greater trochanter will be marked with
the pen, bilaterally;
 During the assessment of the pain threshold on the
tender points, perpendicular pressure will be applied
to the surface of the skin and increased gradually in
increments of 0.1 kg until the patient reports feeling
pain;
 Positive results will be those below 2.6 kg/cm2,
which is equivalent to the 4.0 kg/cm2 described in
studies by Wolfe et al. [21].
Fibromyalgia Impact Questionnaire (FIQ)
The version of the FIQ translated into Portuguese and
validated by Marques (2006) will be used. The FIQ is a
quality of life assessment tool specific to fibromyalgia.
The questionnaire has items addressing functional cap-
acity, professional situation, psychological disorders and
symptoms, for which higher scores denote a greater im-
pact from fibromyalgia on quality of life.
Medical Outcomes Study 36-item Short-Form Health Survey
(SF-36)
The version of the SF-36 translated into Portuguese and
validated by Ciconelli et al. [22] will be used. This is a
generic quality of life assessment tool consisting of 36
items distributed among eight components: functional
capacity (10 items), physical aspects (4 items), pain
(2 items), general health state (5 items), vitality (4 items),
social aspects (2 items), emotional aspects (3 items) and
mental health (5 items) as well as 1 item soliciting a
comparative assessment of current health status with
health status one year earlier. Each component rangesfrom 0 to 100 points, with higher scores denoting a bet-
ter quality of life.
McGill Pain Questionnaire
The McGill Pain Questionnaire (MPQ) adapted to the
Portuguese language will be used [23]. The questionnaire
consists of a list of 78 pain descriptors organized into 4
major categories (sensory, affective, evaluative, and mis-
cellaneous) and 20 subcategories, each made up of at
least 2 and up to 6 words, to which intensity values are
assigned. To calculate Pain Rating Index (PRI) the
descriptors of the third category, which characterizes
pain, will be used. Present Pain Intensity (PPI) will be
evaluated using a verbal scale of pain (0 - no pain,
10 - very strong pain).
As some patients may have difficulty reading and
understanding the instructions of the questionnaires
(McGill Pain Questionnaire, SF-36 and FIQ), the reading
will be performed together with the researchers.
Sleep assessment
The sleep studies will be carried out at the Sleep Labora-
tory of the Post Graduate Program in Rehabilitation
Sciences (UNINOVE) through complete nocturnal
standard level I polysomnography using the Somnolo-
gica Studio (Embla A10 version 3.1.2, Medcare Flaga,
Hs. Medical Devices, Reykjavik, Iceland), composed of
16 channels for the monitoring of electroencephalogram,
electrooculogram, electromyography of the submentum
and tibialis anterior muscles and electrocardiogram, in-
cluding channels for digital oximetry, nasal pressure
(canulla), pressure transducer, respiratory movements
(Xtrace thoracic and abdominal straps) and body pos-
ition. The assessments will be performed manually by a
specialized reader following the guidelines of the Ameri-
can Academy of Sleep Medicine [24], and the criteria of
the Brazilian Sleep Society and the report of the results
will be drafted by a specialist in sleep medicine. The Ber-
lin Questionnaire will be administered also. This 10-item
patient history questionnaire has recognized efficacy in
differentiating individuals with a greater risk of sleep
apnea. Moreover, the Epworth Sleepiness Scale (Johns,
1991) [25] will be employed for the assessment of exces-
sive daytime sleepiness.
Regarding the performance of the examinations and
procedures during the sleep study, the patients will be
instructed to remain as relaxed as possible and sleep
naturally as if at home. All signals will be recorded con-
tinuously throughout the entire sleep period of each
subject.
Educative session
The educative session will be individual and carried out
following the initial evaluation. The subject will be
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symptoms, treatment (stressing the importance of exer-
cise) and consequences for activities of daily living. Some
exercise strategies will be taught, such as extra body
weight loading and adequate positions for the perform-
ance of activities of daily living and practice (work). A
basic exercise program will then be taught, composed of
11 exercises for stretching the gluteus, paravertebral,
hamstrings, pectoral, scalene, intercostals and trapezius
muscles. The patients will receive a chart with all the in-
formation on fibromyalgia as well as illustrations and
descriptions of the exercises to perform. The chart will
be furnished to all patients in order to increase compli-
ance with the at-home exercise program.
Low-level laser therapy
Specifications
The Twin Laser (MM Optics Ltda., São Carlos, São
Paulo, Brazil) will be employed, the active medium of
which is made up of a Gallium-Aluminum-Arsenide
semiconductor diode, with emission in the 780 nm near
infrared wavelength (invisible) and variable power values
in the continuous emission mode. The display provides
the doses according to the power and application time.
The laser will undergo verification of functioning, energy
source, points of application and measurement of power.
To provide the ‘blinding’ of the study, the laser equip-
ment has two identical application points furnished by
the manufacturer - one active and the other a placebo
(that does not emit energy); both have a sound device
and guide light. The points will be named A and B by a
researcher who will not participate in the treatment or
evaluations. The researcher performing the applications
and the evaluators will be unaware of which points
received the effective dose and which received the pla-
cebo. The patients will also not have access to informa-
tion regarding to which group they belong. The points
will be identified only at the end of the data acquisition
phase.
Application of laser
Both groups will receive three laser applications per
week for four weeks, totaling twelve sessions. The appli-
cations will be performed in spot form with direct con-
tact between the laser probe and the skin. However, only
the patients in the effective radiation group with receive
an energy dose of 6 J per point. The application points
will be performed at the tender points identified prior to
each session.
Exercises
Both groups (LLLT and control) will undergo a 50-
mintue exercise program following the application of the
laser or placebo, which will consist of 10 minutes ofwarm up and stretching, 30 minutes of aerobic exercise
on a treadmill and 10 minutes of relaxation and stretch-
ing, three times a week throughout the four weeks of the
study.
Evaluation of results
The intention-to-treat analysis will be followed. The
patients will be evaluated with regard to the primary
outcome (pain) using the visual analog scale for pain,
the McGill Pain Questionnaire and pressure algometry.
The secondary outcome (quality of life) will be assessed
using the SF-36 and FIQ. The use of medication will be
controlled throughout the study. The data on the use of
analgesics and daily dosage of adjuvant therapy, such as
antidepressants and muscle relaxers, will be recorded
and tabulated.
Statistical analysis
ANOVA test with repeated measurements for the time
factor will be performed to test between-groups differ-
ences (followed by the Tukey-Kramer post hoc test), and
a paired t test will be performed to test within-group dif-
ferences. The level of significance for the statistical ana-
lysis will be set at 5% (P ≤0.05).
Discussion
According to data obtained from World Health
Organization, a large number of people around the
world suffer with chronic pain and it reflects in physical
incapacity related to work activities. Furthermore,
chronic pain represents a limiting factor in quality of life
in modern society. Recent studies have shown that 10%
of world population suffers with diffuse chronic pain,
and 2 to 5% of these cases are related to fibromyalgia
[26-28].
Billions of American dollars are expended around the
world every year in diagnostics, treatment, lost workdays
and judicial process due chronic pain. In some cases, the
cause of pain can be due fibromyalgia. Therefore, the
development of efficient therapies can also represent
an important decrease in financial costs in relation
to chronic pain related to musculoskeletal disorders
[29-31].
LLLT has been widely used in treatment of skeletal
muscle disorders with positive results [32-35]. The light-
tissue interaction (photobiostimulation) leads to anal-
gesic and anti-inflammatory effects [36], and also
improves tissue healing [37]. With this perspective in
mind, we can expect that LLLT in addition to exercise
will significantly decrease pain and improve quality of
life in these patients.
Finally, with the development of the protocol of this
study, it is expected that the group treated with LLLT
will present with significant reduction of pain intensity
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threshold, and improvement in the overall quality of life
and quality of sleep.
Trial status
At the time of manuscript submission the patients are
being recruited to trial.
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